Abstract OBJECTIVES: The role of perioperative chemotherapy (POC) and targeted therapies in lung metastasectomy for colorectal cancer (CRC) is still subject to debate. We aimed to evaluate whether POC and targeted therapies were associated with different outcomes according to the mutational status.
INTRODUCTION
Colorectal cancer (CRC) is the third most frequently diagnosed cancer in the world, accounting for nearly 10% of all cancers worldwide [1] . In Europe, with 450 000 new cases and 215 000 deaths in 2012, CRC was the second most commonly diagnosed cancer and the second leading cause of death [2] . Up to 50% of these patients will experience metastases during their lives, mainly located in the liver and lung [3] . Even though to date, there has been no published prospective randomized study, a very large majority of surgical teams consider resection of both hepatic and pulmonary metastases as the standard of care in selected patients [4] . Although lung metastasectomy for CRC remains a subject of debate, a systematic review concluded that the 5-year overall survival (OS) ranged from 40% to 68% after complete resection of lung metastases [5] , which is higher than expected with the standard chemotherapy administered in unresected metastatic CRC [6] . A recent pooled analysis confirmed this result with a report that the 5-year OS after lung metastasectomy reached 54.3% [7] . Lung resection always alters respiratory function and is potentially associated with significant morbidity. Consequently, to select patients who would most likely benefit from surgery, several risk factors for a poor outcome following lung metastasectomy have been identified. Factors, such as a high preoperative carcinoembryonic antigen level, thoracic lymph node involvement (LNI), liver metastases, short disease free survival (DFS), number of thoracic metastases and incomplete resection, have been associated with poor outcomes [8] . More recently, an increased understanding of molecular alterations in cancer cells has led to the identification of two potentially useful proto-oncogenes: VKi-ras2 Kirsten sarcoma viral oncogene homologue (KRAS) and Vraf Murine sarcoma viral oncogene homologue B1 (BRAF). Previous series have reported a shorter OS and recurrence free survival rate after lung metastasectomy for CRC in patients harbouring these mutations [9, 10] .
With respect to resectable liver metastases, the European Organization for Research and Treatment of Cancer 40983 study reported a survival benefit associated with perioperative chemotherapy (POC) compared with surgery alone [11] , making POC a part of the management of resectable liver metastases. However, because of the paucity of data, the role of POC in lung metastasectomy for CRC is still controversial.
The aim of our study was to evaluate the benefit of POC in a large cohort of patients following lung metastasectomy for CRC. Specifically, we sought to determine whether the mutational status (i.e. KRAS and BRAF) was associated with different outcomes.
MATERIALS AND METHODS
This study was approved by the Ethics Committee of the French Society of Thoracic and Cardiovascular Surgeons (Approval Number: CERC-SFCTCV-2016-2-26-9-40-45-ReSt). We retrospectively reviewed the data from 308 unselected and consecutive patients with metastatic CRC who underwent a lung metastasectomy in the Thoracic Surgery Department of Strasbourg University Hospital (France) from January 1998 to December 2015 for whom the mutational status was known (i.e. KRAS and BRAF). The main part of the cohort was previously published [10] and was supplemented with 43 new patients who underwent surgery between January 2012 and December 2015. Patients for whom mutational status was unknown were excluded from this study (n = 85). All the new cases included patients who were considered completely cured of their primary tumour at the time of the thoracic metastasectomy, and there were no synchronous metastases. Only patients with hepatic metastases were included. Thoracic procedures were performed by thoracotomy, in order to palpate lung parenchyma aiming to detect metastases not seen at the preoperative imaging. All thoracic resections were considered R0.
Preoperative thoracic evaluation, the lung metastasectomy procedure and the molecular analysis, covariates and data collection were performed as previously published [10] .
Because patients were referred to our Department of Thoracic Surgery by various oncologists from different centres, no uniform protocol of chemotherapy was performed. However, chemotherapy regimens generally consisted of fluoropyrimidines (5-fluorouracil), administered alone or in combination with oxaliplatin (Folfox/XelOx regimens) and/or irinotecan (Folfiri/Folfoxiri regimens). Finally, in some cases, bevacizumab was added at the discretion of the oncologist. The timing of chemotherapy was defined as follows: neoadjuvant chemotherapy administered prior to thoracic surgery, adjuvant chemotherapy administered following lung metastasectomy, and POC was performed both in neoadjuvant and adjuvant settings.
Statistical analysis
IBM SPSS (Armonk, NY, USA) v.20 was used for statistical analyses. Comparisons between groups were performed with Chi-square, Fisher or Student's t-tests when appropriate. The prognostic influence of variables on survival was assessed with a log-rank test and Cox proportional hazard models. All tests were two sided, and the variables were considered significant for P-values <0.01 in order to limit inflation of alpha risk. All variables with P-values <0.2 were tested in a multivariate analysis.
RESULTS
The median follow-up time was 57 months (min: 1, max: 122). The median age at the time of thoracic metastasectomy was 61 years old (interquartile range: 16). The mean number of resected metastases was 2.9 (SD: ±1.7). A lobectomy was performed in 29 patients (13%), a segmentectomy in 22 (10%) and wedge resections in 172. The demographic data of the population are presented in Table 1 according to the type of chemotherapy performed, and in the Supplementary Table S1 according to the mutational status. With reference to the KRAS mutational status, we observed 43 G12D (35%), 28 G12V (23%), 30 G13D (25%), 9 G12C (7.4%), 8 G12S (7%) and 4 G12A (3%) mutations. With reference to the chemotherapy regimen: 167 (74%) patients benefited from chemotherapy; among them, 67 (30%) patients benefited from bevacizumab during their course: 19 (28%) during the neoadjuvant period, 30 during the adjuvant period (45%) and 18 (27%) as perioperative treatment. Otherwise, according to the mutational status, 33 (44%) wild-type (WT) patients, 31 (25%) KRAS mutation (mKRAS) patients and 3 (12%) BRAF mutation (mBRAF) patients benefited from bevacizumab.
No bronchopleural fistulas were noted, although 18 (8%) prolonged air leaks (>7 days) were noted. The percentage of prolonged air leak was not significantly different for patients who benefit from bevacizumab (n = 7, 10/5%) compared with those who did not (n = 11, 7%) (P = 0.42).
Overall survival
The median OS of the entire cohort was 94 months [95% confidence interval (CI): 79.04-108.96], with a corresponding 1-, 2-, 3-and 5-year OS of 96%, 89%, 82% and 71%, respectively. In the univariate analysis, although OS was better in cases that received chemotherapy (whether adjuvant, neoadjuvant or perioperative timing), the difference in OS did not reach significance [ Finally, in a univariate analysis, CCI (P < 0.001), the pT stage of the primary CRC (P < 0.001), thoracic LNI (P < 0.001), multiple thoracic metastasis (P = 0.003), history of liver metastasis (P = 0.01) and mutational status (P < 0.001) significantly impacted OS. The data are compiled in the Supplementary Table S2 .
In the multivariate analysis, absence of bevacizumab, although only approaching significance, was associated with a poorer prognosis [hazard ratio (HR): 2.11 (0.99-4.53), P = 0.055]. Otherwise, low CCI (P < 0.001), pT1 stage of the primary CRC (P < 0.001), absence of thoracic LNI (P < 0.001) and mutational status (i.e. mKRAS and WT compared with mBRAF, P < 0.001) were favourable independent prognostic factors. The data are compiled in the Supplementary 
Loco-regional recurrence free survival
At the end of the follow-up, 117 (52%) patients had experienced a thoracic recurrence. The median LRRFS for the entire cohort was 50 months (95% CI: 44.46-55.34) with a corresponding 1-, 2-, 3-and 5-year LRRFS of 66%, 62%, 60% and 31%, respectively. In the univariate analysis, although LRRFS was better for cases that received chemotherapy [50 months (95% CI: 43.77-56.23) vs 21 months (95% CI: 0-52.65)], the median LRRFS was not significantly influenced by administration of chemotherapy (P = 0.21). When analysed according to the timing of chemotherapy ( Fig.  2A) In the univariate analysis, the median LRRFS was significantly influenced by the pT of the primary tumour (P < 0.001), the pN of the primary tumour (P < 0.001), thoracic LNI (P = 0.04), multiple thoracic metastasis (P < 0.001) and the mutational status (P < 0.001). The data are presented in the Supplementary Table S3 .
In the multivariate analysis, the absence of bevacizumab was associated with a poorer prognosis [HR: 4.05 (95% CI: 2.2-7.45), P < 0.001]. Finally, a low pT stage of the primary tumour (P < 0.001), the pN0 of the primary CRC (P = 0.004) and the mutational status (i.e. absence of mBRAF, P < 0.001) were favourable prognostic factors. The data are presented in the Supplementary Material, Table S3 .
DISCUSSION
The role of chemotherapy in the surgical management of lung metastases from CRC is not clearly defined. Two main questions remain unanswered: (i) Does chemotherapy improve both OS and LRRFS? (ii) What is the best timing for therapy? To date, the published literature provides no answers to these questions. Published series on pulmonary metastasectomy from CRC have focused on numerous prognostic factors, including the administration of chemotherapy; however, specific outcomes of these subgroups of patients have rarely been specifically investigated. Only a few retrospective studies with small cohorts have focused on POC. In a study with 221 patients, including 176 receiving adjuvant chemotherapy, Park et al. [12] concluded that DFS was improved in cases of adjuvant chemotherapy administration (32.7 vs 11.2 months, P = 0.076). However, the authors did not observe an impact of adjuvant chemotherapy on OS (89.6 vs 86.8 months, P = 0.833). In another study involving 51 patients, Hawkes et al. [13] concluded that adjuvant chemotherapy increased both 5-year OS (74% vs 68%) and recurrence free survival (38% vs 18%). However, in this study, data on outcomes according to the timing of chemotherapy were not available. In a retrospective study of 229 patients, 49% of whom received neoadjuvant chemotherapy, Subbiah et al. [14] reported a significantly increased progression free survival in cases receiving neoadjuvant chemotherapy (18.8 vs 18.1 months, P = 0.004), although the difference was not clinically significant. In our study, we observed that even though non-significant, administration of chemotherapy was associated with an increase in both OS and LRRFS, particularly in the adjuvant settings. This observation favours the use of adjuvant chemotherapy following lung metastasectomy, especially because neoadjuvant chemotherapy may potentially delay the surgical procedure resulting in an unresectable lesion at the end of the treatment. Furthermore, previous authors have demonstrated that in the neoadjuvant setting, the incidence of toxicity may be increased [15] . It is important to note, however, that even if neoadjuvant chemotherapy seems to lead to poorer results, particularly in terms of LRRFS, significantly more patients with mBRAF who experienced the worst OS and LRRFS were included in this group. This may partially explain the poorer OS and LRRFS related to neoadjuvant chemotherapy.
One previous study that specifically presented data on the use of bevacizumab in lung metastasectomy from CRC [14] concluded that there was no benefit (median OS: 51.5 vs 55.1 months, P = 0.435). However, in this study, only 47 patients received bevacizumab therapy. In our study, the use of bevacizumab was associated with an increased median OS and LRRFS in both the univariate and multivariate analyses, particularly when used in the adjuvant setting. Here again, this observation strongly supports the practice of administering adjuvant therapy following lung metastasectomy. Interestingly, we observed that the benefit of bevacizumab was only evident in patients with a KRAS exon 2 codon 12 mutation. To the best of our knowledge, our study is Figure 2 : Kaplan-Meier loco-regional recurrence free survival according to (A) whether chemotherapy was or was not received (i.e. neoadjuvant, adjuvant or perioperative chemotherapy); (B) whether bevacizumab was or was not used; (C) whether bevacizumab was or was not administered to patients with mKRAS.
the first to report this benefit following lung metastasectomy for CRC. In a previous report on metastatic CRC, Dadduzio et al. [16] also reported a benefit on OS in cases that added bevacizumab to the treatment regimen of patients with mKRAS codon 12 mutations, with no advantage noted in patients with codon 13 mutations. A growing number of publications support the existence of multiple types of KRAS mutations due to KRAS amino acid substitutions that lead to different behaviours among cancer cells [17] . Interestingly, previous reports have shown that KRAS codon 12 mutations, but not codon 13 mutations, are associated with an upregulation of vascular endothelial growth factor (VEGF), which is implicated in the promotion of lymphangiogenesis [18] . More recently, Schweiger et al. [19] demonstrated that increased lymphangiogenesis is associated with lymph node recurrence and decreased OS. Thus, the benefit of bevacizumab may be partly due to its inhibitory effects on VEGF. Furthermore, this may also partially account for the decrease in OS and the high rate of thoracic LNI that we observed in mKRAS patients, both in this study and in our previous publication [10] . The real benefit of bevacizumab and how long it should be used in an adjuvant setting still need to be questioned. In the National Surgical Adjuvant Breast and Bowel Project Phase III trial comparing adjuvant bevacizumab with FOLOFOX6 versus FOLFOX6 alone in Stages II-III colon cancer, Allegra et al. [20] did not report a benefit of bevacizumab on DFS, although an initial positive effect was observed on the experimental group during the exposition period. This observation led the authors to hypothesize that bevacizumab had a biological effect on cancer cells during exposition, followed by a rebound effect after its discontinuation. This study, however, did not take into account patients' molecular statuses. We did not observe a benefit of bevacizumab in either patients with mBRAF mutations or WT patients, although the former subgroup was very small. Consequently, more studies on the chemosensitivity of tumours according to mutational status are required to better adapt and target therapies.
Delayed healing has been related to perioperative use of bevacizumab. It is consequently usually recommended to not use bevacizumab 4-6 weeks in the perioperative period. We did not observe in our cohort any complication, more particularly prolonged air leak, related to its use. Consequently, this time period seems to be more than reasonable to avoid major complications such as delayed bronchial stump healing. However, our population is highly selected, and no firm conclusions can be drawn from our observation.
Our results must be interpreted with caution based on a few limitations. First, it is a retrospective cohort study with a relatively small sample size. More specifically, because of the retrospective nature of the cohort, data on extrathoracic recurrence were not available and would be interesting to study in prospective studies. Furthermore, the molecular data were obtained from the primary CRC and not from the metastatic tumours. Consequently, there is remaining doubt on the degree of concordance between the primary and metastatic tumours, although Cejas et al. [21] reported a concordance rate of 94%. Our study also covers a 13-year period during which the management of patients may have changed, and the different chemotherapy regimens used may have also influenced the survival of the study participants. However, a long study period was required to obtain enough statistical power.
In conclusion, to the best of our knowledge, this is the first study to report the benefit of bevacizumab administration in lung metastasectomy for CRC in patients harbouring KRAS exon 2 codon 12 mutations. Chemotherapy, such as bevacizumab, appears to be beneficial in the adjuvant setting in increasing both OS and LRRFS. We strongly believe that molecular markers may be useful in selecting appropriate candidates for metastasectomy and for guiding the adjuvant treatment regimen because the response to chemotherapy and targeted therapies seems to differ according to the mutational status and may be routinely used in the future. We advocate again that although patients with mBRAF mutations are not good candidates for surgery, long-term OS and PFS can be achieved in patients with mKRAS mutations thanks to bevacizumab. Nonetheless, our results must be interpreted with caution considering the limitations listed above. More studies are necessary to evaluate the sensitivity of cancer cells according to their mutational status to better adapt the chemotherapy regimen.
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